An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice
- 1 January 2022
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 914, 174635
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81430082)
- Double First Class University Plan (CPU2018GF08)
- Priority Academic Program Development of Jiangsu Higher Education Institutions
This publication has 30 references indexed in Scilit:
- Increase of INS-1 cell apoptosis under glucose fluctuation and the involvement of FOXO–SIRT pathwayDiabetes Research and Clinical Practice, 2012
- Impact of weight gain on outcomes in type 2 diabetesCurrent Medical Research and Opinion, 2011
- Regulatory challenges for new drugs to treat obesity and comorbid metabolic disordersBritish Journal of Clinical Pharmacology, 2009
- Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implicationsDiabetologia, 2009
- Inhibition of GIP signaling modulates adiponectin levels under high-fat diet in miceBiochemical and Biophysical Research Communications, 2008
- Targeted Ablation of Glucose-dependent Insulinotropic Polypeptide-producing Cells in Transgenic Mice Reduces Obesity and Insulin Resistance Induced by a High Fat DietJournal of Biological Chemistry, 2008
- Overexpression of a dominant negative GIP receptor in transgenic mice results in disturbed postnatal pancreatic islet and beta-cell developmentRegulatory Peptides, 2004
- Effectiveness and Toxicity Screening of Various Absorption Enhancers in the Rat Small Intestine: Effects of Absorption Enhancers on the Intestinal Absorption of Phenol Red and the Release of Protein and Phospholipids from the Intestinal MembraneJournal of Pharmacy and Pharmacology, 1996
- Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.Journal of Clinical Investigation, 1993
- Penetration and enzymatic barriers to peptide and protein absorptionAdvanced Drug Delivery Reviews, 1989